

NAMSDL



National Alliance for Model State Drug Laws

SYNTHETIC CANNABINOID TRADE NAME AND CHEMICAL COMPOUND CHART

This project was supported by Cooperative Agreement No. 2012-DC-BX-K002 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the office of Juvenile Justice and Delinquency Prevention, the office for Victims of Crime, the Community Capacity Development Office, and the Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the U.S. Department of Justice.

The following chart may not include all trade or other names for the designated substances. It also may not include all variations in the chemical composition of the substance.

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namSDL.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Trade or Other Name	Chemical Compound
2NE1	N-adamantyl-1-pentylindole-3-carboxamide
5-bromopentyl-UR-144, 5-bromo-UR-144	[1-(5-bromopentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone
5-chloropentyl-UR-144, 5-chloro-UR-144	[1-(5-chloropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone
5-fluoropentyl-UR-144, 5-fluoro-UR-144	[1-(5-fluoropentylindol-3-yl)]-(2,2,3,3-tetramethylcyclopropyl)methanone
A-796,260	1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; OR {1-[2-(4-morpholinyl)ethyl]indol-3-yl}-(2,2,3,3-tetramethylcyclopropyl)methanone
A-834,735	1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
A-836,339	N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide
AB-001	1-pentyl-3-(1-adamantoyl)indole
AB-034	[1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
AKB-48	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; OR 1-pentyl-N-tricyclo[3.3.1.1 ^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
AM-087	(6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
AM-356; methanandamide	(5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl]icosa-5,8,11,14-tetraenamide; OR arachidonyl-1'-hydroxy-2'-propylamide
AM-411	(6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
AM-630	6-Iodopravadoline; OR 1-[2-(morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole
AM-661	1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole
AM-679	1-pentyl-3-(2-iodobenzoyl)indole
AM-694	1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; OR 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone
AM-855	(4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol
AM-905	(6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol
AM-906	(6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol
AM-1220	(R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone; OR 1-((N-methylpiperidin-2-

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	yl)methyl)-3-(1-naphthoyl)indole; OR 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole
AM-1221	1-[(N-methylpiperidin-2-yl)methyl]-2-methyl-3-(naphthalen-1-oyl)-6-nitroindole
AM-1235	1-[(5-fluoropentyl)-6-nitro-1H-indol-3-yl]-(naphthalen-1-yl)methanone
AM-1241	1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole
AM-1248	1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole
AM-2201	1-(5-fluoropentyl)-3-(1-naphthoyl)indole
AM-2232	1-(4-cyanobutyl)-3-(naphthalen-1-oyl)indole; OR 5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanenitrile
AM-2233	1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole
AM-2389	(6aR,9R,10aR)-3-(1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol
BAY 38-7271	(-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate
Cannabicyclohexanol, C8 homologue of CP 47,497	5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; OR 5-(1,1-dimethyloctyl)-2-(3-hydroxycyclohexyl)-phenol
Cannabipiperidiethanone	1-(N-methylpiperidin-2-ylmethyl)-3-(2-methoxyphenylacetate)indole; OR 2-(2-methoxyphenyl)-1-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]ethanone
CB-13, SAB-378	Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone
CP 47,497	5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; OR 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol; OR [2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol]; OR 5-(1,1-dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol; OR 2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol
CP 47,497 homologues	Known as the C6, C7, C8 or C9 homologues and also the dimethylhexyl, dimethyloctyl or dimethylnonyl homologues
CP 50,556-1, Levonantradol	9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; OR [(6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate; OR [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate
CP 55,490	2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol
CP 55,940	2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol
CP 56,667	
HU-210	(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	ol; OR [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol
HU-211, Dexanabinol	(6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
HU-243	3-dimethylheptyl-11-hydroxyhexahydrocannabinol
HU-308	[(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
HU-331	3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione
JTE-907	N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyl-1,2-dihydroquinoline-3-carboxamide
JWH Compounds, misc.	JWH-004; JWH-009; JWH-011; JWH-020; JWH-022; JWH-030; JWH-031; JWH-046; JWH-047; JWH-048; JWH-049; JWH-050; JWH-051; JWH-057; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079; JWH-080; JWH-082; JWH-094; JWH-096; JWH-116; JWH-120; JWH-133; JWH-145; JWH-146; JWH-147; JWH-148; JWH-149; JWH-150; JWH-156; JWH-166; JWH-171; JWH-180; JWH-181; JWH-182; JWH-185; JWH-189; JWH-192; JWH-193; JWH-194; JWH-195; JWH-196; JWH-197; JWH-202; JWH-204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-211; JWH-212; JWH-213; JWH-220; JWH-234; JWH-235; JWH-236; JWH-237; JWH-239; JWH-240; JWH-241; JWH-242; JWH-243; JWH-244; JWH-245; JWH-246; JWH-248; JWH-249; JWH-253; JWH-258; JWH-262; JWH-292; JWH-293; JWH-302; JWH-303; JWH-304; JWH-305; JWH-306; JWH-308; JWH-309; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-316; JWH-346; JWH-348; JWH-359; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; JWH-370; JWH-371; JWH-373; JWH-386; JWH-387; JWH-392; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; JWH-412; JWH-413; JWH-414; JWH-415; JWH-424
JWH-007	1-pentyl-2-methyl-3-(1-naphthoyl)indole
JWH-015	(2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; OR 1-propyl-2-methyl-3-(1-naphthoyl)indole; OR (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone
JWH-016	(1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone
JWH-018, AM-678	1-pentyl-3-(1-naphthoyl)indole; OR naphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(naphthoyl)indole
JWH-019	naphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-hexyl-3-(1-naphthoyl)indole; OR 1-hexyl-3-(naphthoyl)indole; OR 1-hexyl-3-(naphthalen-1-oyl)indole
JWH-073	1-butyl-3-(1-naphthoyl)indole; OR naphthalene-1-yl-(1-

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	butylindol-3-yl)methanone; OR 1-butyl-3-(naphthoyl)indole
JWH-081	4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen-1-yl-(1-pentylindole-3-yl) methanone; OR 1-pentyl-3-[1-(4-methoxynaphthoy)]indole
JWH-098	1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone
JWH-122	1-pentyl-3-(4-methyl-1-naphthoyl)indole; OR (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone
JWH-164	1-pentyl-3-(7-methoxy-1-naphthoyl)indole; OR 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone
JWH-167	1-pentyl-3-(phenylacetyl)indole
JWH-175	3-(naphthalen-1-ylmethyl)-1-pentyl-1H-indole; OR 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane
JWH-176	E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane
JWH-184	1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane
JWH-199	
JWH-200	1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole; OR (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone; OR [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone; OR 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole
JWH-201	1-pentyl-3-(4-methoxyphenylacetyl)indole; OR 1-pentyl-3-(4-methoxyphenylacetyl)indole
JWH-203	2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-chlorophenylacetyl)indole
JWH-210	4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-ethyl-1-naphthoyl)indole
JWH-250	2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-methoxyphenylacetyl)indole; OR 1-pentyl-3-(methoxyphenylacetyl)indole; OR 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone
JWH-251	2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; OR 1-pentyl-3-(2-methylphenylacetyl)indole
JWH-307	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone
JWH-398	1-pentyl-3-(4-chloro-1-naphthoyl)indole
MAM-2201	4-methyl-1-naphthalenyl(1-fluoropentyl-1H-indol-3-yl)methanone
RCS-4, SR-19	[(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone]; OR 1-pentyl-3-[(4-methoxy)-benzoyl]indole; OR 1-pentyl-3-(4-methoxybenzoyl)indole; OR (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone
RCS-8	1-(2-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	methoxyphenylethanone); OR 1-[2-(2-cyclohexylethyl)-1H-indol-3-yl]-2-methoxyphenylethanone; OR 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
STS-135	N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide
UR-144; fluoro-UR-144; 5-fluoro-UR-144	(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; OR N-(5-chloropentyl) analog
URB-597	[3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate
URB-602	[1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; OR cyclohexyl [1,1'-biphenyl]-3-ylcarbamate
URB-754	6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one
URB-937	3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate
WIN 48,098, Pravadoline	(4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone; OR (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone
WIN 55,212-2	(R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone; OR [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
XLR-11	(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
DEA Proposed Generic Language	<p>The term Cannabimimetic Agents means, collectively, the chemicals that meet the criteria of any one or more of paragraphs (a) through (e). Any substance within the structural classes identified below that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays:</p> <p>(a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.</p> <p>(b) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.</p> <p>(c) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.</p> <p>(d) 1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene ring, whether or not further substituted in</p>

© 2013 Research is current as of February 14, 2013. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

	<p>the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.</p> <p>(e) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</p>
<p>ACMD Suggested Generic Language 1</p>	<p>Naphthoylindoles and naphthylmethylindoles – Any compound structurally derived from 3-(1-naphthoyl) indole, 3-(2-naphthoyl) indole, 1H-indol-3-yl-(1-naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.</p> <p>Naphthoylpyrroles – Any compound structurally derived from 3-(1-naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.</p> <p>Naphthylmethylindenes – Any compound structurally derived from 1-(1-naphthylmethylene)indene or 1-(2-naphthylmethylene)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.</p> <p>Phenylacetylindoles – Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.</p>

	<p>Cyclohexylphenols – Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.</p>
ACMD Suggested Generic Language 2	<p>Categories from Generic Language 1 plus:</p> <p>Benzoylindoles – Any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.</p> <p>Adamantoylindoles – Any compound structurally derived from 3-(1-adamantoyl) indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.</p> <p>Tetramethylcyclopropylindoles – Any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent.</p>
Generic Language – Additional Derivative Language (Bold)	<p>Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.</p>

	<p>Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.</p> <p>Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent.</p> <p>Naphthylmethylindenenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2 (4 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent.</p> <p>Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent.</p> <p>Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-</p>
--	---

	<p>piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not substituted in the cyclohexyl ring to any extent.</p> <p>Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.</p> <p>Adamantoylindoles. Any compound structurally derived from 3-(1-adamantoyl) indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent.</p> <p>Tetramethylcyclopropanoylindoles. Any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent.</p>
--	--